KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to 15.45%.

  • Travere Therapeutics' EBITDA Margin rose 1016100.0% to 15.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.32%, marking a year-over-year increase of 1511300.0%. This contributed to the annual value of 137.31% for FY2024, which is 616100.0% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' EBITDA Margin is 15.45%, which was up 1016100.0% from 11.12% recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' EBITDA Margin registered a high of 406.89% during Q3 2023, and its lowest value of 329.91% during Q1 2024.
  • For the 5-year period, Travere Therapeutics' EBITDA Margin averaged around 119.2%, with its median value being 112.28% (2021).
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 6500700bps in 2023, then plummeted by -4930500bps in 2024.
  • Travere Therapeutics' EBITDA Margin (Quarter) stood at 32.61% in 2021, then plummeted by -821bps to 235.29% in 2022, then rose by 17bps to 195.25% in 2023, then soared by 59bps to 79.33% in 2024, then skyrocketed by 119bps to 15.45% in 2025.
  • Its EBITDA Margin was 15.45% in Q3 2025, compared to 11.12% in Q2 2025 and 51.37% in Q1 2025.